B3GNT3 and cervical carcinoma: Immunohistochemistry (IHC) was performed to investigate the expression pattern of B3GNT3 protein in a retrospective cohort of 193 cervical cancer cases, including 85 cases of stage IB1 (44.1%), 29 cases of stage IB2 (15.0%), 56 cases of stage IIA1 (29.0%) and 23 cases of stage IIA2 (11.9%).